Keratoconus is a rare, progressive ophthalmic disorder characterized by changes to the cornea that result in significant vision loss. Epioxa is an oxygen-enriched, UV-bioactivated topical treatment ...

Please provide your email address to receive an email when new articles are posted on . Corneal tissue addition keratoplasty, or CTAK, is a novel intrastromal lamellar keratoplasty technique for the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Epion Therapeutics has initiated its phase 3 Apricity ...

BURLINGTON, Mass.--(BUSINESS WIRE)--Epion Therapeutics (Epion) announced the commencement of its Phase 3 Apricity trials for EpiSmart™, the company’s minimally-invasive keratoconus therapy. This marks ...

Glaukos Corporation GKOS recently announced the commercial availability of Epioxa, marking a significant milestone in its corneal health portfolio. The therapy stands out as the first FDA-approved, ...

Add Yahoo as a preferred source to see more of our stories on Google. The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal ...

Keratoconus is a progressive eye condition that affects the shape and clarity of the cornea, often beginning in the teenage years or early adulthood. As the cornea thins and bulges into a cone-like ...

On Monday, Glaukos Corporation (NYSE:GKOS) received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for ...

Two surgical procedures have been described for ICRS implantation: the mechanical method and the femtolaser method. The use of femtolaser for ICRS tunnel creation was widely accepted after FDA ...

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus, a Sight-Threatening Rare Disease ALISO VIEJO, Calif., ...

The average per-person inflation-adjusted lifetime cost of keratoconus treatment in 2019 was nearly $29,000, with a cumulative economic burden of $3.8 billion, a large retrospective cohort study ...